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ABSTRACT 
Background: Cysteinyl-leukotrienes are lipid derived mediators involved in asthma. They are able to stimulate 
eosinophil chemotaxis in vitro. Induced sputum from asthmatics has been shown to contain eosinophil 
chemotactic activity. The purpose of our study was to evaluate the contribution of cysteinyl-leukotrienes to 
sputum eosinophil chemotactic activity in asthmatics and to seek whether there might be differences between 
asthmatics free of inhaled corticosteroids vs those regularly receiving this treatment. Methods: Twenty-two 
patients (11 corticosteroid free, mean FEV1 99% predicted, 11 corticosteroid-treated, mean FEV1 77% predicted) 
recruited from our asthma clinic underwent a sputum induction. Sputum was processed according to standard 
procedure. Eosinophil chemotactic activity contained in the fluid phase was assessed using Boyden 
microchamber model and expressed as chemotaxis index (CI). Cysteinyl-leukotrienes were measured in sputum 
supernatant by ELISA and their role in sputum eosionophil chemotactic activity was evaluated by using 
montelukast, a selective antagonist of a cys-LT1 receptor. Results: Cysteinyl-leukotrienes were well detectable 
in sputum supernatants from both steroid-naive (247 ± 42 pg/ml) and steroid-treated (228 ± 26 pg/ml) 
asthmatics. Sputum eosinophil chemotactic activity was indiscriminately present in both corticosteroid-naive 
(CI: 2.61 ± 0.22) and corticosteroid-treated (2.98 ± 0.35) asthmatics. Montelukast (100 µM) significantly 
inhibited the eosinophil chemotactic activity in both groups achieving a mean inhibition of 54.2 ± 9.2% (P < 
0.001) and 64.7 ± 7.8% (P < 0.001) in steroid-naive and steroid-treated asthmatics respectively. Conclusion: 
Cysteinyl-leukotrienes actively participate in sputum eosinophil chemotactic activity found in asthmatics 
irrespective of whether they are or not under treatment with inhaled corticoids. 
Keywords : asthma ; cysteinyl-leukotrienes ; sputum eosinophil chemotactic activity. 
 
 
Airways eosinophilia is a prominent feature of classic asthma as well as cough variant asthma (1, 2). Although 
sputum eosinophil count only plays a limited role in determining airways hyperresponsiveness to methacholine 
(3) and acute and late airways obstruction following an allergen inhalation in asthmatics (4), it still might be 
relevant to the mechanisms leading to a loss of disease control (5, 6) or to an asthma exacerbation (7). This 
might be linked to the fact that high sputum eosinophil count seems to be associated with a lack of plateau 
during a metacholine bronchial provocation (2). 
Induced sputum is a useful tool to monitor airway allergic inflammation (8). We have previously shown that 
induced sputum from asthmatics contained eosinophil chemotactic activity not found in healthy subjects (9). 
Cysteinyl-leukotrienes are mediators endowed with chemotactic activity towards eosinophils in vitro (9, 10). 
Inhalation of cysteinyl leukotrienes results in a rise in sputum eosinophil counts within a few hours (11). 
Cysteinyl-leukotrienes levels were found to be raised in sputum from asthmatics and correlated with asthma 
severity (12). 
The purpose of our work was to investigate the contribution of cysteinyl-leukotrienes to sputum eosinophil 
chemotactic activity in asthmatics. Therefore we measured the levels of cysteinyl-leukotrienes as well as the 
eosinophil chemotactic activity in sputum supernatants and assessed the impact of montelukast, a cysteinyl-
leukotrienes receptor antagonist, on sputum chemotactic activity from both corticosteroid-naive and 
corticosteroid-treated asthmatics. 
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Material and methods 
Subjects 
Twenty-two subjects were recruited from our asthma clinic to undergo a sputum induction. Asthma was defined 
as a clinical history of recurrent wheeze, breathlessness or cough associated with either bronchial 
hyperresponsiveness to methacholine (PC20 M ≤ 16 mg/ml) or FEV1 reversibility > 12% to inhaled 400 µg 
salbutamol. Eleven of them were regularly treated with inhaled corticoids with an average dosage of 1560 µg 
equivalent BDP per day (range from 400 µg to 2000 µg) and seven of them received a combination of inhaled 
corticoids and long acting β2 agonists. None of them were receiving theophylline. Their demographic, functional 
and sputum characteristics are given in Table 1. The protocol of the study was approved by our local ethical 
committee and each subject gave written informed consent. 
 
Table 1: Demographic and functional characteristics and sputum cell counts in steroid-naive and steroid-treated 
asthmatics 
 Steroid naive (n = 11) Steroid treated (n = 11) 
Age 40 (18) 46 (17) 
Sex 6 M/5F 5M/6 F 
FEV1 (% predicted) 99.2 (25.6) 77 (27.4) 
Squamous cells, % 35.3 (16-55) 21.6 (0-57) 
Total nonsquamous 0.6 (0.3-1.24) 0.78 (0.36-1.9) 
cells, × 106/g   
Macrophages, % 40.8 (22.8-90) 21.8 (5-88.8) 
Lymphocytes, % 0.8 (0-3.8) 1.2 (0.4-4.6) 
Neutrophils, % 29.4 (0.2-61.6) 34 (0-92.2) 
Eosinophils, % 11.6 (0-28.8) 1.6 (0-52.2) 
Epithelial cells, % 7 (1-38) 2 (0-39) 
Age and FEV1 values are expressed as mean (SD). Sputum cell counts results are expressed as median (range). 
 
Sputum induction and processing 
Hypertonic saline solution (NaCl 4.5%) was aerosolized by an ultrasonic nebulizer (Ultra Neb 2000; De Vilbiss, 
Feltham, Middlesex, UK) with output set at 1.5 ml/min. The subjects wearing a nose clip inhaled aerosol through 
a mouthpiece during 10-15 min. Sputum was collected and the whole sputum processed as previously described 
in order to perform total and differential counts and to assess biological activity of the fluid phase of the samples 
(3). 
Eosinophil isolation and chemotaxis 
Granulocytes were isolated from heparin-anticoagulated peripheral blood of a mild asthmatic volunteer not 
taking inhaled corticoids. Eosinophils were purified (99%) by immunomagnetic cell separation (MACS; 
Miltenyi Biotec, Bergisch Gladbach, Germany), using anti-CD16 as described by Hatzelman et al. (13). 
Chemotaxis assays for eosinophils were performed using micro-Boyden chambers (Neuroprobe, Gaithersburg, 
MD). Experiments were performed in triplicate in a 48-well microchemotaxis Boyden chamber incubated in 5% 
CO2 at 37°C for 60 min. Aliquots of 25 µl of chemotactic agents like Platelet-activating factor 0.1 µM (PAF, 
Sigma, St Louis, MO), cysteinyl-leukotriene D4 (LTD4; Caiman, Ann Arbor, MI) or sputum supernatants were 
placed in the lower wells and 50 µl of eosinophil suspension (106 cells/ml) were placed in the upper wells. The 
two chambers were separated by a polyvinyl pyrrolidone free filter (Nucleopore, Whatman, Middlesex, UK). 
The controls consisted of a solution of Hank's balanced salt solution (HBSS) with Ca2+ (pH 7.4). The filters were 
fixed in methanol and stained with Diff-Quick. Migrated cells adherent to the lower surface were counted in 10 
fields/well under a light microscope with a magnification x600. In experiments investigating the effect of 
montelukast (10 nM to 100 µM; Merck, Sharpe and Dohne, Rahway, NJ) the drug was added to sputum 
supernatants, LTD4 or PAF and let for 90 min for incubation prior to chemotaxis assay. Montelukast was also 
added at the same concentration to the eosinophil suspension in the upper chamber. The results were expressed 
as the chemotactic index (CI) that is the number of cells having migrated in the presence of the chemotactic 
agent or the sputum divided by the number of cells having migrated in the presence of HBSS alone. 
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Cysteinyl-leukotrienes immunoassay 
Cysteinyl-leukotrienes were measured by enzyme immunoassay employing a cysteinyl-leukotriene polyclonal 
antiserum (Cayman Chemical, Ann Arbor, MI) after prior purification on C18 columns (Varian, INC, Canada). 
The recovery rate was 80% and samples were corrected accordingly. The sensitivity of the ELISA was 7 pg/ml. 
Statistical analyses 
According to the normality of the distribution based on Kolmogorov-Smirnov results for chemotaxis 
experiments were expressed as mean ± SEM while those of sputum cysteinyl-leukotrienes levels were expressed 
as median (range). Assessment of the CI of pharmacological agents or sputum supernatants was performed by 
using a one sample 't' test with an hypothetical value of 1 representing the CI of HBSS. Assessment of the 
inhibitory effect of montelukast on chemotaxis was performed by using a paired Student 't' test. P-values <0.05 
were considered as statistically significant. 
Results 
Effect of LTD4 on eosinophil chemotaxis in Boyden microchambers model  
LTD4 caused a dose-related eosinophil chemotactic activity in the range of 0.001-10 nM with a significant effect 
(P < 0.05) at 0.001 nM (Fig. 1). The chemotactic activity generated by LTD4 (0.7 nM) was strongly inhibited by 
montelukast 100 µM, a specific cyst-LTl receptor antagonist (89 ± 1%). By contrast montelukast was completely 
unable to inhibit the chemotactic activity generated with PAF 100 nM (Fig. 2) 
Cysteinyl-leukotrienes as factors contributing to sputum eosinophil chemotactic activity 
Sputum cysteinyl-leukotrienes levels were 215 pg/ml (94-565) and 161 pg/ml (119-434) and not significantly 
different in steroid-naive (n = 11) and steroid-treated asthmatics (n= 11) respectively (P = 0.72). This range of 
concentrations approximately corresponds to 0.2-1 nM, that is a concentration range endowed with significant 
chemotactic activity for human eosinophils in vitro as described in Fig. 1. 
Significant sputum eosinophil chemotactic activity was present in both steroid-naive (CI: 2.61 ± 0.22; P < 
0.0001) and steroid-treated asthmatics (CI: 2.98 ± 0.35; P < 0.0001) and not significantly different between the 
groups (P = 0.47). There was no significant relationship between sputum eosinophil chemotactic and eosinophil 
counts in any of the two groups (r = -0.22; P = 0.36 in corticosteroid-naive and r = 0.20; P = 0.41 in 
corticosteroid-treated patients respectively). Montelukast 100 µM caused a mean inhibition of sputum eosinophil 
chemotactic activity reaching 54.2 ± 9.2% (P < 0.0001) and 64.7 ± 7.8% (P < 0.001) in steroid-naive and 
steroid-treated asthmatics respectively (Fig. 3). The extent of inhibition afforded by montelukast was not 
significantly different between the two groups of asthmatics. 
 
Figure 1: Eosinophil chemotaxis induced by LTD4 (0.001-10 nM) and PAF (100 nM) in the Boyden 
microchamber model. Results are expressed as mean ± SEM (n = 4). *Chemotactic index significantly different 
(P < 0.05) from 1 which is the value obtained with HBSS alone. 
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Figure 2: Specific inhibitory effect of Montelukast (100 µM) on eosinophil chemotaxis induced by LTD4 (10-10 
M) and PAF (10-7 M). Results are expressed as mean ± SEM (n = 3). The SEM (0.02) is so small for the bar 
LTD4 + MT that it does not appear graphically. 
 
 
Figure 3: Inhibition   by   montelukast   of   sputum   eosinophil chemotactic activity (SI) in steroid-naive 
(hatched bars, n = 11) and steroid-treated asthmatics (squared bars, n = 11). MT = montelukast 100 µM. 




Sputum supernatants from asthmatics contain measurable amounts of cysteinyl-leukotrienes which did not differ 
between those receiving or not receiving regular treatment with inhaled corticosteroids. Our study shows, for the 
first time, that cysteinyl-leukotrienes may contribute to the eosinophil chemotactic activity found in the sputum 
from both corticosteroid-naive and corticosteroid-treated asthmatics. 
We found that sputum supernatant from asthmatics contains detectable amounts of cysteinyl-leukotrienes, which 
is in keeping with previous studies performed in asthmatics (12, 14). The range of cysteinyl-leukotriene 
concentrations we found here is somewhat lower than that reported by Pavord and coworkers (12, 14). There is 
however a potential explanation for this observation as the latter authors used the plug of the sputum sample 
whereas we used the whole sample. As the plug method is recognized to concentrate the biochemical compounds 
in the fluid phase (14, 15), it appears logical to find lower concentrations in the supernatant coming from the 
whole samples. Interestingly the concentrations of cysteinyl-leukotrienes measured in our supernatants were 
shown to exhibit clear eosinophil chemotactic activity in vitro. This is an important observation which made 
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cysteinyl-leukotrienes potential contributors to chemotactic activity exhibited by sputum supernatants. The 
confirmation for this hypothesis came from the demonstration that montelukast, a cystLT1 receptor antagonist, 
was able to decrease the sputum eosinophil chemotactic activity by 50-60%. The residual chemotactic activity of 
sputum samples is likely to be dependent on the presence in the fluid phase of other chemotactic agents than 
cysteinyl-leukotrienes. It is worth noting that montelukast possessed similar inhibitory effect on samples from 
asthmatics irrespective of whether they were or not currently treated with inhaled corticosteroids. This goes in 
line with the documented inability of corticosteroids to adequately control the release of cysteinyl-leukotrienes in 
the airways of asthmatics (16). The extent of inhibition obtained in our study is slightly lower than that achieved 
with a specific monoclonal antibody directed towards eotaxin which was shown to range from 52% to 86% 
inhibition in moderate to severe asthma (17). Our finding complements the data from Dent et al. and show that, 
besides eotaxin, cysteinyl-leukotrienes also contribute to the eosinophil chemotactic activity. Interestingly we 
found here that cysteinyl-leukotrienes were involved in mild asthma which was not the case for eotaxin, the 
contribution of which mainly prevailed in moderate to severe asthma (17). 
In agreement with Dent et al. (17) we did not find relationship between sputum eosinophil counts and the 
chemotactic activity towards this cell type. This highlights the  complexity  of  the  mechanisms   involved   in   
the regulation of the number of eosinophils present in the airways. In this regard it has recently been suggested 
that priming of circulating eosinophils is a critical step prior to cell extravasation and tissular recruitment (18). 
Although the group receiving inhaled corticosteroids and still displaying reduced FEV1 values has to be 
considered as more severe than the corticosteroid-naive group displaying normal FEV1, the extent of sputum 
chemotactic activity was rather similar between the groups. This argues against a clear link between the 
magnitude of sputum chemotactic activity and asthma severity which is in keeping with Dent's study (17). The 
question as to whether inhibition of sputum eosinophil chemotaxis has impact that may translate into clinical 
benefit is not resolved by our study. 
In conclusion, cysteinyl-leukotrienes significantly contribute to the eosinophil chemotactic activity contained in 
sputum from asthmatics. The proportion of this contribution is similar between mild and moderate to severe 
asthmatics and not affected by regular treatment with inhaled corticosteroids. 
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